379 related articles for article (PubMed ID: 11788125)
1. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
Sacks FM
Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Després JP
Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
[TBL] [Abstract][Full Text] [Related]
4. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
5. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Devroey D; Velkeniers B; Duquet W; Betz W
Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
[TBL] [Abstract][Full Text] [Related]
6. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
7. Taking aim at HDL-C. Raising levels to reduce cardiovascular risk.
McGovern ME
Postgrad Med; 2005 Apr; 117(4):29-30, 33-5, 39 passim. PubMed ID: 15842130
[TBL] [Abstract][Full Text] [Related]
8. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
[TBL] [Abstract][Full Text] [Related]
9. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
10. Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Kris-Etherton PM
Curr Atheroscler Rep; 2001 Nov; 3(6):435-6. PubMed ID: 11602062
[No Abstract] [Full Text] [Related]
11. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
12. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
Boden WE; Pearson TA
Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
[TBL] [Abstract][Full Text] [Related]
13. Treating mixed dyslipidemias: why and how.
Ballantyne CM
Clin Cardiol; 2001; 24(7 Suppl):II-6-9. PubMed ID: 11444652
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
15. Low high-density lipoprotein cholesterol: current status and future strategies for management.
Singh V; Sharma R; Kumar A; Deedwania P
Vasc Health Risk Manag; 2010 Oct; 6():979-96. PubMed ID: 21127701
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
Stokić E; Marinkov J
Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
18. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
19. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
Pirillo A; Norata GD; Catapano AL
Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430
[TBL] [Abstract][Full Text] [Related]
20. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
